The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data

The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data

Abstract Background The majority of Plasmodium falciparum malaria cases in Africa are treated with the artemisinin combination therapies artemether-lumefantrine (AL) and artesunate-amodiaquine (AS-AQ), with amodiaquine being also widely used as part of seasonal malaria chemoprevention programs combi...

Full description

Bibliographic Details
Main Authors: Michael T. Bretscher, Prabin Dahal, Jamie Griffin, Kasia Stepniewska, Quique Bassat, Elisabeth Baudin, Umberto D’Alessandro, Abdoulaye A. Djimde, Grant Dorsey, Emmanuelle Espié, Bakary Fofana, Raquel González, Elizabeth Juma, Corine Karema, Estrella Lasry, Bertrand Lell, Nines Lima, Clara Menéndez, Ghyslain Mombo-Ngoma, Clarissa Moreira, Frederic Nikiema, Jean B. Ouédraogo, Sarah G. Staedke, Halidou Tinto, Innocent Valea, Adoke Yeka, Azra C. Ghani, Philippe J. Guerin, Lucy C. Okell
Format: Article
Language:English
Published: BMC 2020-02-01
Series:BMC Medicine
Subjects:
Malaria
Artemisinin
Drug
Lumefantrine
Amodiaquine
Trial
Online Access:http://link.springer.com/article/10.1186/s12916-020-1494-3

Internet

http://link.springer.com/article/10.1186/s12916-020-1494-3

Similar Items